PERTH, Australia and LELYSTAD, The Netherlands, May 10, 2011 /PRNewswire/ -- Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, and Pepscan Therapeutics, a Dutch biopharmaceutical firm focusing on protein mimicry technology, today announce that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery.

LELYSTAD, The Netherlands, March 10, 2011 /PRNewswire/ -- Pepscan Therapeutics, the Dutch biotechnology firm focusing on protein mimicry technology, today announces that it has signed a Research and License Agreement with Crucell Holland B.V.

LELYSTAD, The Netherlands, September 14, 2010 /PRNewswire/ -- Pepscan Therapeutics (Pepscan), the Netherlands based biotechnology firm focusing on protein mimicry technology for the generation of novel therapeutics, today announced that it has signed a Research and License Agreement with Tibotec Pharmaceuticals, Ireland (Tibotec).

LELYSTAD, The Netherlands, March 10 /PRNewswire/ -- Pepscan Therapeutics (Pepscan) today announced that it has earned a milestone payment from Genmab A/S. The milestone payment arises from an ongoing Research Collaboration aimed at identifying human antibodies against intractable targets.

COPENHAGEN, Denmark and LELYSTAD, Netherlands, March 3 /PRNewswire-FirstCall/ -- Genmab A/S and Pepscan today announced the start of a research collaboration aimed at identifying fully human monoclonal antibodies against intractable disease targets.